Viracta Therapeutics, Inc.
Records under this name other than the patents Viracta Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Viracta Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,932,246 | Histone Deacetylase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 8,802,657 | Compounds Useful as Raf Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 9,556,177 | Substituted 1,3-Thiazoles as Synthetic Intermediates for Preparation of Raf Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 9,920,048 | Substituted Pyrimidines for Inhibiting Raf Kinase Activity Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,857,152 | Methods and Compositions for Treating Viral or Virally-Induced Conditions Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,083,119 | Methods and Compositions for Treating Viral or Virally-Induced Conditions Formerly held In force · Low confidence | In force | Low confidence | |
| US 8,293,752 | Compounds Useful as Raf Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 12,427,152 | Hdac Inhibitors for Use with NK Cell Based Therapies Formerly held In force · High confidence | In force | High confidence | |
| US 10,953,011 | Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,760,748 | Hdac Inhibitor Solid State Forms Formerly held In force · Low confidence | In force | Low confidence |